Clinical Studies

Verdinexor is a chemotherapy drug that has been conditionally approved by the FDA for the treatment of canine lymphoma. Verdinexor is a selective inhibitor of nuclear export (SINE) compound, and this family of drug has demonstrated encouraging results in preclinical studies when combined with other chemotherapeutic drugs.

Ethos Discovery now seeks to deliver a highly advanced clinical trial program investigating the use of novel drugs for the treatment of Hemangiosarcoma (HSA) with the goal of curing this aggressive cancer. This study will ask if drugs specifically matched to the genomic subtypes of patients with HSA will result in improved outcomes.

Intestinal dysbiosis has been associated with tumor progression of colorectal, lung, and breast cancer in human patients. The objective of this study is to determine whether or not canine patients diagnosed with osteosarcoma have intestinal dysbiosis and if the presence of intestinal dysbiosis is associated with metastasis in these patients.